However, the aim of this article is to provide a more comprehensive review of recently obtained knowledge regarding specifically underlying molecular and cellular mechanisms of GLP1 effects on hepatic lipid metabolism and its potential in the treatment of NAFLD. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.